Skip to Content
Merck
All Photos(1)

Documents

N0750000

Nifedipine

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

1,4-Dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic acid dimethyl ester

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C17H18N2O6
CAS Number:
21829-25-4
Molecular Weight:
346.33
MDL number:
MFCD00057326
UNSPSC Code:
41116107
PubChem Substance ID:
329818455
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

nifedipine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

COC(=O)C1=C(C)NC(C)=C(C1c2ccccc2[N+]([O-])=O)C(=O)OC

InChI

1S/C17H18N2O6/c1-9-13(16(20)24-3)15(14(10(2)18-9)17(21)25-4)11-7-5-6-8-12(11)19(22)23/h5-8,15,18H,1-4H3

InChI key

HYIMSNHJOBLJNT-UHFFFAOYSA-N

Gene Information

human ... CACNA1C(775) , CACNA1D(776) , CACNA1F(778) , CACNA1S(779)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Nifedipine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302

Precautionary Statements

P301 + P312 + P330

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

11 - Combustible Solids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Neeraj Dhaun et al.
Journal of the American Society of Nephrology : JASN, 24(1), 31-36 (2012-12-18)
Arterial stiffness and impaired nitric oxide (NO) bioavailability contribute to the high risk for cardiovascular disease in CKD. Both asymmetric dimethylarginine (ADMA), an endogenous inhibitor of NO production, and endothelin-1 (ET-1) oppose the actions of NO, suggesting that ET-1 receptor
C B Wilcox et al.
BJOG : an international journal of obstetrics and gynaecology, 118(4), 423-428 (2011-01-05)
The success rates of external cephalic version (ECV) are improved with the use of betamimetic tocolytics, but these drugs are associated with maternal side effects. To critically evaluate the effectiveness and advantages, if any, of nifedipine as a tocolytic for
Sho-ichi Yamagishi et al.
Current medicinal chemistry, 15(2), 172-177 (2008-01-29)
Dihydropyridine-based calcium antagonists (DHPs) are widely used drugs for the treatment of hypertension and angina pectoris. We, along with others, have recently found that nifedipine, one of the most widely used DHPs, inhibits apoptotic cell death of endothelial cells (ECs)
Yoshiki Yui
Drugs, 66 Spec No 1, 25-27 (2008-01-19)
It is thought that coronary artery spasm is involved in the pathogenesis of coronary artery disease in a large proportion of Japanese patients. However, large-scale trial data in Japanese patients were lacking. The JMIC-B (Japan Multicenter Investigation for Cardiovascular Diseases-B)
Corey B Toal et al.
Blood pressure, 21 Suppl 1, 3-10 (2012-07-06)
Calcium-channel blockers (CCBs) constitute a diverse group of compounds but are often referred to as a single homogeneous class of drug and the clinical responses indiscriminately summarized. Even within the dihydropyridine subgroup, there are significant differences in formulations, pharmacokinetics, durations
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service